Brokers Set Expectations for Zura Bio FY2026 Earnings

Zura Bio Limited (NASDAQ:ZURA - Free Report) - Equities research analysts at Cantor Fitzgerald issued their FY2026 EPS estimates for shares of Zura Bio in a research note issued on Monday, June 9th. Cantor Fitzgerald analyst J. Schimmer expects that the company will earn ($0.63) per share for the year. The consensus estimate for Zura Bio's current full-year earnings is ($0.65) per share.

A number of other brokerages have also commented on ZURA. Oppenheimer decreased their price objective on shares of Zura Bio from $19.00 to $17.00 and set an "outperform" rating on the stock in a report on Friday, May 9th. Chardan Capital decreased their price objective on shares of Zura Bio from $12.00 to $10.00 and set a "buy" rating on the stock in a report on Wednesday, March 26th. HC Wainwright reissued a "buy" rating on shares of Zura Bio in a report on Thursday, April 3rd. Finally, Guggenheim restated a "buy" rating and set a $15.00 target price on shares of Zura Bio in a research report on Wednesday, March 26th. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, Zura Bio currently has an average rating of "Buy" and an average target price of $14.33.

Zura Bio Stock Down 1.6%

NASDAQ:ZURA traded down $0.02 during mid-day trading on Wednesday, reaching $1.20. 246,298 shares of the company were exchanged, compared to its average volume of 436,398. Zura Bio has a 12 month low of $0.97 and a 12 month high of $5.07. The company has a fifty day moving average of $1.21 and a 200 day moving average of $1.61. The stock has a market cap of $82.05 million, a PE ratio of -1.71 and a beta of -0.12.

Zura Bio (NASDAQ:ZURA - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.19) EPS for the quarter, missing analysts' consensus estimates of ($0.17) by ($0.02).

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. SG Americas Securities LLC lifted its position in Zura Bio by 51.6% during the 4th quarter. SG Americas Securities LLC now owns 23,005 shares of the company's stock valued at $58,000 after purchasing an additional 7,828 shares during the period. Wells Fargo & Company MN raised its position in shares of Zura Bio by 68.6% in the 4th quarter. Wells Fargo & Company MN now owns 23,053 shares of the company's stock valued at $58,000 after acquiring an additional 9,379 shares during the period. Bank of America Corp DE raised its position in shares of Zura Bio by 31.9% in the 4th quarter. Bank of America Corp DE now owns 41,222 shares of the company's stock valued at $103,000 after acquiring an additional 9,966 shares during the period. Rhumbline Advisers raised its position in shares of Zura Bio by 37.3% in the 4th quarter. Rhumbline Advisers now owns 37,657 shares of the company's stock valued at $94,000 after acquiring an additional 10,231 shares during the period. Finally, American Century Companies Inc. acquired a new stake in shares of Zura Bio in the 4th quarter valued at approximately $27,000. 61.14% of the stock is currently owned by institutional investors and hedge funds.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.